MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers, with the first trials to be launched in 2019.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news